Literature DB >> 35072913

Hyperuricemia aggravates the progression of IgA nephropathy.

Yin-Hong Geng1, Zhe Zhang1, Jun-Jun Zhang1, Bo Huang1, Zui-Shuang Guo1, Xu-Tong Wang1, Lin-Qi Zhang2, Song-Xia Quan1, Rui-Min Hu1, Ya-Fei Liu3.   

Abstract

OBJECTIVE: The relationship between hyperuricemia and IgA nephropathy (IgAN) was evaluated systematically in this research.
METHODS: The Preferred Reporting Items for Systematic Review and Meta-analysis statement was employed to design and report the study.
RESULTS: Twenty-five studies were included in this meta-analysis with a total of 6048 IgAN patients. The clinical indicators indicated that blood urea nitrogen (BUN) (p < 0.00001, mean difference (MD) = 2.60, 95% confidence interval (CI) 1.74-3.46), serum creatinine (Scr) (p < 0.00001, MD = 44.56, 95% CI 31.15-57.98), diastolic blood pressure(DBP) (p < 0.00001, MD = 3.86, 95% CI 2.84-4.88), systolic blood pressure(SBP) (p < 0.00001, MD = 6.71, 95% CI 4.70-8.71), and 24-h urine protein(24 h TP) (p < 0.00001, MD = 0.76, 95% CI 0.58-0.94) were significantly increased in IgAN with hyperuricemia group than that in normouricemic IgAN group. The pathological analysis indicated that mesangial proliferation (p < 0.00001, MD = 0.12, 95% CI 0.07-0.17), vascular lesion (p < 0.00001, MD = 0.17, 95% CI 0.13-0.20), segmental lesion (p < 0.00001, MD = 0.15, 95% CI 0.03-0.26), tubulointerstitial damage (p < 0.00001, MD = 1.27, 95% CI 1.06-1.48), and glomerulosclerosis (p < 0.00001, MD = 0.56, 95% CI 0.40-0.72) were considerably climbed in IgAN patients with hyperuricemia compared without hyperuricemia group. Additionally, the estimated glomerular filtration rate (p < 0.00001, MD = - 29.03, 95% CI - 36.83 to - 21.23) was decreased in IgAN patients with hyperuricemia compared with normouricemic group.
CONCLUSION: Hyperuricemia exacerbates IgAN prognosis through aggravating the clinical outcomes and pathological results of IgAN.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Hyperuricemia; IgA nephropathy; Meta-analysis; Prognosis; Progression

Mesh:

Substances:

Year:  2022        PMID: 35072913     DOI: 10.1007/s11255-022-03125-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  23 in total

1.  Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial.

Authors:  Yongjun Shi; Wei Chen; Diana Jalal; Zhibin Li; Wenfang Chen; Haiping Mao; Qiongqiong Yang; Richard J Johnson; Xueqing Yu
Journal:  Kidney Blood Press Res       Date:  2011-11-23       Impact factor: 2.687

2.  High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a.

Authors:  Takahito Moriyama; Mitsuyo Itabashi; Takashi Takei; Hiroshi Kataoka; Masayo Sato; Ari Shimizu; Yuko Iwabuchi; Miki Nishida; Keiko Uchida; Kosaku Nitta
Journal:  J Nephrol       Date:  2014-10-30       Impact factor: 3.902

3.  Hyperuricemia is associated with progression of IgA nephropathy.

Authors:  Ali Bakan; Alihan Oral; Omer Celal Elcioglu; Mumtaz Takir; Osman Kostek; Abdullah Ozkok; Semih Basci; Abdullah Sumnu; Savas Ozturk; Murat Sipahioglu; Aydın Turkmen; Luminita Voroneanu; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-03-12       Impact factor: 2.370

4.  A role for uric acid in the progression of renal disease.

Authors:  Duk-Hee Kang; Takahiko Nakagawa; Lili Feng; Susumu Watanabe; Lin Han; Marilda Mazzali; Luan Truong; Raymond Harris; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

5.  Uric acid excretion and dopamine-induced glomerular filtration response in patients with IgA glomerulonephritis.

Authors:  Beata Sulikowska; Jacek Manitius; Grazyna Odrowaz-Sypniewska; Wiesława Łysiak-Szydłowska; Bolesław Rutkowski
Journal:  Am J Nephrol       Date:  2007-12-07       Impact factor: 3.754

6.  Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up.

Authors:  Gen-yang Cheng; Dong-wei Liu; Na Zhang; Lin Tang; Zhan-zheng Zhao; Zhang-suo Liu
Journal:  Clin Nephrol       Date:  2013-07       Impact factor: 0.975

7.  IgA nephropathy: morphologic predictors of progressive renal disease.

Authors:  S M Lee; V M Rao; W A Franklin; M S Schiffer; A J Aronson; B H Spargo; A I Katz
Journal:  Hum Pathol       Date:  1982-04       Impact factor: 3.466

8.  Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan.

Authors:  Takahito Moriyama; Kayu Tanaka; Chihiro Iwasaki; Yasuko Oshima; Ayami Ochi; Hiroshi Kataoka; Mitsuyo Itabashi; Takashi Takei; Keiko Uchida; Kosaku Nitta
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

9.  Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.

Authors:  Danhua Shu; Feifei Xu; Zhen Su; Ji Zhang; Chaosheng Chen; Jianna Zhang; Xiaokai Ding; Yinqiu Lv; Haixia Lin; Peipei Huang
Journal:  BMC Nephrol       Date:  2017-01-07       Impact factor: 2.388

Review 10.  Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis.

Authors:  Rui Liu; Cheng Han; Di Wu; Xinghai Xia; Jianqiu Gu; Haixia Guan; Zhongyan Shan; Weiping Teng
Journal:  Biomed Res Int       Date:  2015-11-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.